<code id='0997A6F051'></code><style id='0997A6F051'></style>
    • <acronym id='0997A6F051'></acronym>
      <center id='0997A6F051'><center id='0997A6F051'><tfoot id='0997A6F051'></tfoot></center><abbr id='0997A6F051'><dir id='0997A6F051'><tfoot id='0997A6F051'></tfoot><noframes id='0997A6F051'>

    • <optgroup id='0997A6F051'><strike id='0997A6F051'><sup id='0997A6F051'></sup></strike><code id='0997A6F051'></code></optgroup>
        1. <b id='0997A6F051'><label id='0997A6F051'><select id='0997A6F051'><dt id='0997A6F051'><span id='0997A6F051'></span></dt></select></label></b><u id='0997A6F051'></u>
          <i id='0997A6F051'><strike id='0997A6F051'><tt id='0997A6F051'><pre id='0997A6F051'></pre></tt></strike></i>

          entertainment

          entertainment

          author:Wikipedia    Page View:652
          The Chamber of Commerce in downtown Washington, DC.
          The U.S. Chamber of Commerce sued to stop a new Medicare drug price negotiation program from going into effect. Adobe

          WASHINGTON — Attorneys for the U.S. Chamber of Commerce and the federal government sparred Friday over whether drugmakers have enough say in Medicare’s new drug price negotiation program, in the first oral arguments in a lawsuit challenging the new law.

          The two sides debated two questions: whether the Chamber of Commerce would be sufficiently injured by the law to file a lawsuit, and whether the negotiation program was a violation of drugmakers’ due process rights.

          advertisement

          The hearing was held in the U.S. District Court for the Southern District of Ohio, and Judge Michael Newman, a Trump nominee, presided. Newman didn’t ask any questions of the attorneys, so the hearing didn’t provide any hints about which way he might be leaning on the issues.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          Albert Bourla of Pfizer: worst biopharma CEO of 2023
          Albert Bourla of Pfizer: worst biopharma CEO of 2023

          HyacinthEmpinado/STATPfizeristhisyear’santi-EliLilly.IfDavidRicksisthebestbiopharmaCEOof2023,thenPfi

          read more
          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more

          In diabetes hearing, Sanders takes on a new foe: food makers

          Sen.BerneSanders(I-Vt.)KevinDietsch/GettyImagesWASHINGTON—Sen.BernieSanders(I-Vt.)hasanewcorporateta